Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 91

1.

An Unstable Monoterpene Alcohol as a Pheromone Component of the Longhorned Beetle Paranoplium gracile (Coleoptera: Cerambycidae).

Collignon RM, Halloran S, Serrano JM, McElfresh JS, Millar JG.

J Chem Ecol. 2019 Apr;45(4):339-347. doi: 10.1007/s10886-019-01063-7. Epub 2019 Mar 11.

PMID:
30854612
2.

Faecal immunochemical tests versus colonoscopy for post-polypectomy surveillance: an accuracy, acceptability and economic study.

Atkin W, Cross AJ, Kralj-Hans I, MacRae E, Piggott C, Pearson S, Wooldrage K, Brown J, Lucas F, Prendergast A, Marchevsky N, Patel B, Pack K, Howe R, Skrobanski H, Kerrison R, Swart N, Snowball J, Duffy SW, Morris S, von Wagner C, Halloran S.

Health Technol Assess. 2019 Jan;23(1):1-84. doi: 10.3310/hta23010.

3.

Faecal immunochemical tests (FIT) versus colonoscopy for surveillance after screening and polypectomy: a diagnostic accuracy and cost-effectiveness study.

Cross AJ, Wooldrage K, Robbins EC, Kralj-Hans I, MacRae E, Piggott C, Stenson I, Prendergast A, Patel B, Pack K, Howe R, Swart N, Snowball J, Duffy SW, Morris S, von Wagner C, Halloran SP, Atkin WS.

Gut. 2019 Sep;68(9):1642-1652. doi: 10.1136/gutjnl-2018-317297. Epub 2018 Dec 11.

4.

Faecal immunochemical tests: when quantitation is not enough.

Halloran SP.

Lancet Gastroenterol Hepatol. 2019 Feb;4(2):83-84. doi: 10.1016/S2468-1253(18)30337-6. Epub 2018 Nov 27. No abstract available.

PMID:
30497963
5.

Intelligent Use of the Fecal Immunochemical Test in Population-Based Screening.

Halloran SP.

Ann Intern Med. 2018 Oct 2;169(7):496-497. doi: 10.7326/M18-2257. Epub 2018 Sep 18. No abstract available.

PMID:
30242365
6.

Fuscumol and Geranylacetone as Pheromone Components of Californian Longhorn Beetles (Coleoptera: Cerambycidae) in the Subfamily Spondylidinae.

Halloran ST, Collignon RM, McElfresh JS, Millar JG.

Environ Entomol. 2018 Oct 3;47(5):1300-1305. doi: 10.1093/ee/nvy101.

PMID:
29986003
7.

Critical research gaps and recommendations to inform research prioritisation for more effective prevention and improved outcomes in colorectal cancer.

Lawler M, Alsina D, Adams RA, Anderson AS, Brown G, Fearnhead NS, Fenwick SW, Halloran SP, Hochhauser D, Hull MA, Koelzer VH, McNair AGK, Monahan KJ, Näthke I, Norton C, Novelli MR, Steele RJC, Thomas AL, Wilde LM, Wilson RH, Tomlinson I; Bowel Cancer UK Critical Research Gaps in Colorectal Cancer Initiative.

Gut. 2018 Jan;67(1):179-193. doi: 10.1136/gutjnl-2017-315333. Review.

8.

Risk-adjusted colorectal cancer screening using the FIT and routine screening data: development of a risk prediction model.

Cooper JA, Parsons N, Stinton C, Mathews C, Smith S, Halloran SP, Moss S, Taylor-Phillips S.

Br J Cancer. 2018 Jan;118(2):285-293. doi: 10.1038/bjc.2017.375. Epub 2017 Nov 2.

10.

Improvements to Phakometry Using Bessel Beams.

Suheimat M, Bhattarai D, Maher HK, Chandra M, Chelepy W, Halloran SK, Lambert AJ, Atchison DA.

Optom Vis Sci. 2017 Nov;94(11):1015-1021. doi: 10.1097/OPX.0000000000001130.

PMID:
28945628
11.

Reducing the socioeconomic gradient in uptake of the NHS bowel cancer screening Programme using a simplified supplementary information leaflet: a cluster-randomised trial.

Smith SG, Wardle J, Atkin W, Raine R, McGregor LM, Vart G, Morris S, Duffy SW, Moss S, Hackshaw A, Halloran S, Kralj-Hans I, Howe R, Snowball J, Handley G, Logan RF, Rainbow S, Smith S, Thomas M, Counsell N, von Wagner C.

BMC Cancer. 2017 Aug 14;17(1):543. doi: 10.1186/s12885-017-3512-1.

12.

Testing innovative strategies to reduce the social gradient in the uptake of bowel cancer screening: a programme of four qualitatively enhanced randomised controlled trials.

Raine R, Atkin W, von Wagner C, Duffy S, Kralj-Hans I, Hackshaw A, Counsell N, Moss S, McGregor L, Palmer C, Smith SG, Thomas M, Howe R, Vart G, Band R, Halloran SP, Snowball J, Stubbs N, Handley G, Logan R, Rainbow S, Obichere A, Smith S, Morris S, Solmi F, Wardle J.

Southampton (UK): NIHR Journals Library; 2017 Mar.

13.

Australian and New Zealand Pulmonary Rehabilitation Guidelines.

Alison JA, McKeough ZJ, Johnston K, McNamara RJ, Spencer LM, Jenkins SC, Hill CJ, McDonald VM, Frith P, Cafarella P, Brooke M, Cameron-Tucker HL, Candy S, Cecins N, Chan AS, Dale MT, Dowman LM, Granger C, Halloran S, Jung P, Lee AL, Leung R, Matulick T, Osadnik C, Roberts M, Walsh J, Wootton S, Holland AE; Lung Foundation Australia and the Thoracic Society of Australia and New Zealand.

Respirology. 2017 May;22(4):800-819. doi: 10.1111/resp.13025. Epub 2017 Mar 24.

PMID:
28339144
14.

Examining the potential use and long-term stability of guaiac faecal occult blood test cards for microbial DNA 16S rRNA sequencing.

Taylor M, Wood HM, Halloran SP, Quirke P.

J Clin Pathol. 2017 Jul;70(7):600-606. doi: 10.1136/jclinpath-2016-204165. Epub 2016 Dec 23.

15.

A national cluster-randomised controlled trial to examine the effect of enhanced reminders on the socioeconomic gradient in uptake in bowel cancer screening.

Raine R, Moss SM, von Wagner C, Atkin W, Hans IK, Howe R, Solmi F, Morris S, Counsell N, Hackshaw A, Halloran S, Handley G, Logan RF, Rainbow S, Smith S, Snowball J, Seaman H, Thomas M, Smith SG, McGregor LM, Vart G, Wardle J, Duffy SW.

Br J Cancer. 2016 Dec 6;115(12):1479-1486. doi: 10.1038/bjc.2016.365. Epub 2016 Nov 22.

16.

Genetic ablation of Smoothened in pancreatic fibroblasts increases acinar-ductal metaplasia.

Liu X, Pitarresi JR, Cuitiño MC, Kladney RD, Woelke SA, Sizemore GM, Nayak SG, Egriboz O, Schweickert PG, Yu L, Trela S, Schilling DJ, Halloran SK, Li M, Dutta S, Fernandez SA, Rosol TJ, Lesinski GB, Shakya R, Ludwig T, Konieczny SF, Leone G, Wu J, Ostrowski MC.

Genes Dev. 2016 Sep 1;30(17):1943-55. doi: 10.1101/gad.283499.116. Epub 2016 Sep 15.

17.

Using a hypothetical scenario to assess public preferences for colorectal surveillance following screening-detected, intermediate-risk adenomas: annual home-based stool test vs. triennial colonoscopy.

Bonello B, Ghanouni A, Bowyer HL, MacRae E, Atkin W, Halloran SP, Wardle J, von Wagner C.

BMC Gastroenterol. 2016 Sep 13;16:113. doi: 10.1186/s12876-016-0517-1.

18.

Increased uptake and improved outcomes of bowel cancer screening with a faecal immunochemical test: results from a pilot study within the national screening programme in England.

Moss S, Mathews C, Day TJ, Smith S, Seaman HE, Snowball J, Halloran SP.

Gut. 2017 Sep;66(9):1631-1644. doi: 10.1136/gutjnl-2015-310691. Epub 2016 Jun 7.

PMID:
27267903
19.

FIT for the future: a case for risk-based colorectal cancer screening using the faecal immunochemical test.

Cooper JA, Moss SM, Smith S, Seaman HE, Taylor-Phillips S, Parsons N, Halloran SP.

Colorectal Dis. 2016 Jul;18(7):650-3. doi: 10.1111/codi.13365.

PMID:
27135192
20.

Reducing the Social Gradient in Uptake of the NHS Colorectal Cancer Screening Programme Using a Narrative-Based Information Leaflet: A Cluster-Randomised Trial.

McGregor LM, von Wagner C, Atkin W, Kralj-Hans I, Halloran SP, Handley G, Logan RF, Rainbow S, Smith S, Snowball J, Thomas MC, Smith SG, Vart G, Howe R, Counsell N, Hackshaw A, Morris S, Duffy SW, Raine R, Wardle J.

Gastroenterol Res Pract. 2016;2016:3670150. doi: 10.1155/2016/3670150. Epub 2016 Mar 16.

21.

Recommendations for a step-wise comparative approach to the evaluation of new screening tests for colorectal cancer.

Young GP, Senore C, Mandel JS, Allison JE, Atkin WS, Benamouzig R, Bossuyt PM, Silva MD, Guittet L, Halloran SP, Haug U, Hoff G, Itzkowitz SH, Leja M, Levin B, Meijer GA, O'Morain CA, Parry S, Rabeneck L, Rozen P, Saito H, Schoen RE, Seaman HE, Steele RJ, Sung JJ, Winawer SJ.

Cancer. 2016 Mar 15;122(6):826-39. doi: 10.1002/cncr.29865. Epub 2016 Feb 1.

22.

Factors associated with completion of bowel cancer screening and the potential effects of simplifying the screening test algorithm.

Kearns B, Whyte S, Seaman HE, Snowball J, Halloran SP, Butler P, Patnick J, Nickerson C, Chilcott J.

Br J Cancer. 2016 Feb 2;114(3):327-33. doi: 10.1038/bjc.2015.469. Epub 2016 Jan 14.

23.

Impact of general practice endorsement on the social gradient in uptake in bowel cancer screening.

Raine R, Duffy SW, Wardle J, Solmi F, Morris S, Howe R, Kralj-Hans I, Snowball J, Counsell N, Moss S, Hackshaw A, von Wagner C, Vart G, McGregor LM, Smith SG, Halloran S, Handley G, Logan RF, Rainbow S, Smith S, Thomas MC, Atkin W.

Br J Cancer. 2016 Feb 2;114(3):321-6. doi: 10.1038/bjc.2015.413. Epub 2016 Jan 7.

24.

Effects of evidence-based strategies to reduce the socioeconomic gradient of uptake in the English NHS Bowel Cancer Screening Programme (ASCEND): four cluster-randomised controlled trials.

Wardle J, von Wagner C, Kralj-Hans I, Halloran SP, Smith SG, McGregor LM, Vart G, Howe R, Snowball J, Handley G, Logan RF, Rainbow S, Smith S, Thomas MC, Counsell N, Morris S, Duffy SW, Hackshaw A, Moss S, Atkin W, Raine R.

Lancet. 2016 Feb 20;387(10020):751-9. doi: 10.1016/S0140-6736(15)01154-X. Epub 2015 Dec 9.

25.

Use of faecal occult blood tests in symptomatic patients.

Steele R, Forgacs I, McCreanor G, Benton S, Machesney M, Rees C, Halloran SP, Abulafi M, Alsina D.

BMJ. 2015 Aug 11;351:h4256. doi: 10.1136/bmj.h4256. No abstract available.

PMID:
26265582
26.

Tests detecting biomarkers for screening of colorectal cancer: What is on the horizon?

Phalguni A, Seaman H, Routh K, Halloran S, Simpson S.

GMS Health Technol Assess. 2015 Jun 10;11:Doc01. doi: 10.3205/hta000122. eCollection 2015.

27.

Faecal occult blood testing for colorectal cancer screening: the past or the future.

Benton SC, Seaman HE, Halloran SP.

Curr Gastroenterol Rep. 2015 Feb;17(2):428. doi: 10.1007/s11894-015-0428-2. Review.

PMID:
25673567
28.

Comment on impact on colorectal cancer mortality of screening programmes based on the faecal immunochemical test.

Logan RF, Halloran SP.

Gut. 2015 Jun;64(6):1006-7. doi: 10.1136/gutjnl-2014-308902. Epub 2014 Dec 15. No abstract available.

PMID:
25512640
29.

Advances in Fecal Occult Blood Tests: the FIT revolution.

Young GP, Symonds EL, Allison JE, Cole SR, Fraser CG, Halloran SP, Kuipers EJ, Seaman HE.

Dig Dis Sci. 2015 Mar;60(3):609-22. doi: 10.1007/s10620-014-3445-3. Epub 2014 Dec 10. Review.

30.

Predictors of repeat participation in the NHS bowel cancer screening programme.

Lo SH, Halloran S, Snowball J, Seaman H, Wardle J, von Wagner C.

Br J Cancer. 2015 Jan 6;112(1):199-206. doi: 10.1038/bjc.2014.569. Epub 2014 Nov 27.

31.

Optimising faecal occult blood screening:retrospective analysis of NHS Bowel Cancer Screening data to improve the screening algorithm.

Geraghty J, Butler P, Seaman H, Snowball J, Sarkar S, Blanks R, Halloran S, Bodger K, Rees CJ.

Br J Cancer. 2014 Nov 25;111(11):2156-62. doi: 10.1038/bjc.2014.480. Epub 2014 Sep 16.

32.

Screening: Colorectal cancer screening--insights and challenges.

Halloran SP.

Nat Rev Gastroenterol Hepatol. 2014 Oct;11(10):586-7. doi: 10.1038/nrgastro.2014.150. Epub 2014 Aug 26.

PMID:
25157621
33.

Turbulent dispersion via fan-generated flows.

Halloran SK, Wexler AS, Ristenpart WD.

Phys Fluids (1994). 2014 May;26(5):055114. Epub 2014 May 30.

34.

Colorectal cancer screening uptake over three biennial invitation rounds in the English bowel cancer screening programme.

Lo SH, Halloran S, Snowball J, Seaman H, Wardle J, von Wagner C.

Gut. 2015 Feb;64(2):282-91. doi: 10.1136/gutjnl-2013-306144. Epub 2014 May 7.

35.

Tests and investigations for colorectal cancer screening.

Carroll MR, Seaman HE, Halloran SP.

Clin Biochem. 2014 Jul;47(10-11):921-39. doi: 10.1016/j.clinbiochem.2014.04.019. Epub 2014 Apr 24. Review.

PMID:
24769265
36.

Population screening for colorectal cancer means getting FIT: the past, present, and future of colorectal cancer screening using the fecal immunochemical test for hemoglobin (FIT).

Allison JE, Fraser CG, Halloran SP, Young GP.

Gut Liver. 2014 Mar;8(2):117-30. doi: 10.5009/gnl.2014.8.2.117. Epub 2014 Mar 11. Review.

37.

Improving the reporting of evaluations of faecal immunochemical tests for haemoglobin: the FITTER standard and checklist.

Fraser CG, Allison JE, Young GP, Halloran SP, Seaman HE.

Eur J Cancer Prev. 2015 Jan;24(1):24-6. doi: 10.1097/CEJ.0000000000000016. No abstract available.

PMID:
24584197
38.

A standard for Faecal Immunochemical TesTs for haemoglobin evaluation reporting (FITTER).

Fraser CG, Allison JE, Young GP, Halloran SP, Seaman H.

Ann Clin Biochem. 2014 Mar;51(Pt 2):301-2. doi: 10.1177/0004563213514392. Epub 2013 Dec 17. No abstract available.

PMID:
24345727
39.

Screening and primary prevention of colorectal cancer: a review of sex-specific and site-specific differences.

Massat NJ, Moss SM, Halloran SP, Duffy SW.

J Med Screen. 2013;20(3):125-48. doi: 10.1177/0969141313501292. Review.

PMID:
24197771
40.

Use of research questionnaires in the NHS Bowel Cancer Screening Programme in England: impact on screening uptake.

Watson J, Shaw K, Macgregor M, Smith S, Halloran S, Patnick J, Beral V, Green J; Bowel Screening Follow-up Study Investigators and Collaborators.

J Med Screen. 2013 Dec;20(4):192-7. doi: 10.1177/0969141313511447. Epub 2013 Oct 31.

PMID:
24177175
41.

Bridging the gap in concussion knowledge.

Halloran SW.

J Neurol Phys Ther. 2013 Dec;37(4):205. doi: 10.1097/NPT.0000000000000021. No abstract available.

PMID:
24162330
42.

Be Well: results of a nutrition, exercise, and weight management intervention among at-risk older adults.

Kogan AC, Gonzalez J, Hart B, Halloran S, Thomason B, Levine M, Enguidanos S.

J Appl Gerontol. 2013 Oct;32(7):889-901. doi: 10.1177/0733464812440043. Epub 2012 Apr 18.

43.

Patient attitudes towards faecal immunochemical testing for haemoglobin as an alternative to colonoscopic surveillance of groups at increased risk of colorectal cancer.

Bowyer HL, Vart G, Kralj-Hans I, Atkin W, Halloran SP, Seaman H, Wardle J, Wagner Cv.

J Med Screen. 2013;20(3):149-56. doi: 10.1177/0969141313503953. Epub 2013 Sep 17.

PMID:
24045920
44.

Volatiles from intact and Lygus-damaged Erigeron annuus (L.) Pers. are highly attractive to ovipositing Lygus and its parasitoid Peristenus relictus Ruthe.

Halloran ST, Mauck KE, Fleischer SJ, Tumlinson JH.

J Chem Ecol. 2013 Aug;39(8):1115-28. doi: 10.1007/s10886-013-0331-y. Epub 2013 Aug 28. Erratum in: J Chem Ecol. 2013 Dec;39(11-12):1448. Fleisher, Shelby F [corrected to Fleischer, Shelby J].

PMID:
23982679
45.

Making colorectal cancer screening FITTER for purpose with quantitative faecal immunochemical tests for haemoglobin (FIT).

Fraser CG, Halloran SP, Allison JE, Young GP.

Clin Chem Lab Med. 2013 Nov;51(11):2065-7. doi: 10.1515/cclm-2013-0408. No abstract available.

PMID:
23787468
46.

Quantitation of hemoglobin improves fecal immunochemical tests for noninvasive screening.

Fraser CG, Allison JE, Young GP, Halloran SP.

Clin Gastroenterol Hepatol. 2013 Jul;11(7):839-40. doi: 10.1016/j.cgh.2013.02.031. Epub 2013 Apr 13. No abstract available.

PMID:
23591278
47.

European guidelines for quality assurance in colorectal cancer screening and diagnosis: overview and introduction to the full supplement publication.

European Colorectal Cancer Screening Guidelines Working Group, von Karsa L, Patnick J, Segnan N, Atkin W, Halloran S, Lansdorp-Vogelaar I, Malila N, Minozzi S, Moss S, Quirke P, Steele RJ, Vieth M, Aabakken L, Altenhofen L, Ancelle-Park R, Antoljak N, Anttila A, Armaroli P, Arrossi S, Austoker J, Banzi R, Bellisario C, Blom J, Brenner H, Bretthauer M, Camargo Cancela M, Costamagna G, Cuzick J, Dai M, Daniel J, Dekker E, Delicata N, Ducarroz S, Erfkamp H, Espinàs JA, Faivre J, Faulds Wood L, Flugelman A, Frkovic-Grazio S, Geller B, Giordano L, Grazzini G, Green J, Hamashima C, Herrmann C, Hewitson P, Hoff G, Holten I, Jover R, Kaminski MF, Kuipers EJ, Kurtinaitis J, Lambert R, Launoy G, Lee W, Leicester R, Leja M, Lieberman D, Lignini T, Lucas E, Lynge E, Mádai S, Marinho J, Maučec Zakotnik J, Minoli G, Monk C, Morais A, Muwonge R, Nadel M, Neamtiu L, Peris Tuser M, Pignone M, Pox C, Primic-Zakelj M, Psaila J, Rabeneck L, Ransohoff D, Rasmussen M, Regula J, Ren J, Rennert G, Rey J, Riddell RH, Risio M, Rodrigues V, Saito H, Sauvaget C, Scharpantgen A, Schmiegel W, Senore C, Siddiqi M, Sighoko D, Smith R, Smith S, Suchanek S, Suonio E, Tong W, Törnberg S, Van Cutsem E, Vignatelli L, Villain P, Voti L, Watanabe H, Watson J, Winawer S, Young G, Zaksas V, Zappa M, Valori R.

Endoscopy. 2013;45(1):51-9. doi: 10.1055/s-0032-1325997. Epub 2012 Dec 4.

48.

European guidelines for quality assurance in colorectal cancer screening and diagnosis. First Edition--Faecal occult blood testing.

Halloran SP, Launoy G, Zappa M; International Agency for Research on Cancer.

Endoscopy. 2012 Sep;44 Suppl 3:SE65-87. Epub 2012 Sep 25.

49.

Socioeconomic variation in uptake of colonoscopy following a positive faecal occult blood test result: a retrospective analysis of the NHS Bowel Cancer Screening Programme.

Morris S, Baio G, Kendall E, von Wagner C, Wardle J, Atkin W, Halloran SP, Handley G, Logan RF, Obichere A, Rainbow S, Smith S, Snowball J, Raine R.

Br J Cancer. 2012 Aug 21;107(5):765-71. doi: 10.1038/bjc.2012.303. Epub 2012 Aug 2.

50.

The impact of media coverage of the Flexible Sigmoidoscopy Trial on English colorectal screening uptake.

Lo SH, Vart G, Snowball J, Halloran SP, Wardle J, von Wagner C.

J Med Screen. 2012 Jun;19(2):83-8. doi: 10.1258/jms.2012.012017. Epub 2012 May 31.

PMID:
22653573

Supplemental Content

Loading ...
Support Center